Skip to main content
Premium Trial:

Request an Annual Quote

Genentech Exec Joins Axys Pharmaceuticals

Premium

SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals announced that John Wulf, formerly director of business development for Genentech, where he was employed for 17 years, has joined Axys as vice-president of business development. Wulf will manage business development in areas of genomics and small-molecule drug development. He reports directly to Daniel Petree, CEO of the life sciences firm here. Petree said Wulf's background will be an asset to Axys as the company expands its efforts toward broad collaborations in inflammatory diseases, metabolic disorders, and oncology.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.